Imagine two people with identical fasting glucose levels and identical A1C scores. On paper, their metabolic health looks the same. But inside their bodies, a very different story is unfolding. The first person’s blood sugar rises modestly after meals and returns smoothly to baseline within two hours. The second person’s glucose spikes sharply, crashes below baseline, rebounds, and repeats the cycle throughout the day. Both would pass a standard metabolic screening with flying colors. Yet some researchers argue that only the first is showing a clearly healthy pattern.
This gap between what standard testing captures and what is really happening inside the body has driven one of the most significant shifts in metabolic medicine over the past decade. Researchers, clinicians, and an increasingly engaged public are now focusing on a concept called glycemic variability, the degree to which blood sugar fluctuates across hours and days. Thanks largely to the widespread adoption of continuous glucose monitors (CGMs), it is now possible to measure this variability in granular detail, and what scientists are finding is rewriting some long-held assumptions about what it means to have healthy blood sugar.
Why Average Glucose Tells Only Half the Story
For decades, the gold standard of blood sugar assessment has been the hemoglobin A1C test, which estimates average blood glucose over roughly three months. Alongside fasting glucose, A1C has been the primary tool for diagnosing prediabetes and type 2 diabetes, and for managing those conditions once diagnosed. It is useful. It is also incomplete.
The analogy that researchers often reach for is this: imagine you want to know how safely someone drove their car. You could average their speed over a three-month road trip. But that average would tell you nothing about whether they drove 90 miles per hour on a school zone road and coasted at 10 miles per hour on the highway. The average obscures the behavior that actually causes harm.
Glycemic variability works similarly. Studies have shown that individuals with the same average blood glucose can have dramatically different patterns of peaks and troughs, and those patterns carry independent health consequences. In people with type 1 diabetes, for example, high glucose variability is associated with a higher risk of hypoglycemic episodes. Researchers have also begun examining variability in type 2 diabetes and in people without any diabetes diagnosis.
The key metrics researchers use to quantify variability include the coefficient of variation (CV), mean amplitude of glycemic excursions (MAGE), and time in range (TIR), the percentage of time glucose stays within a target band, typically 70 to 180 mg/dL for people with diabetes. Time in range has gained particular traction because it is intuitive, actionable, and strongly correlated with outcomes. A consensus statement from leading diabetes organizations recommended a TIR target of above 70 percent for most people with diabetes, based on its association with lower rates of diabetic complications.
The Biology of the Spike: Why Glucose Swings Are Damaging
To understand why variability matters, you need to understand what happens to cells and blood vessels during a glucose spike. When blood sugar rises sharply after a meal, the body releases a surge of insulin to bring it back down. If cells are insulin-sensitive and functioning well, this process is smooth and efficient. If they are not, the spike persists longer, the insulin response is exaggerated or blunted in dysfunctional ways, and the resulting biochemical environment is toxic to tissues.
High glucose concentrations activate a process called oxidative stress, flooding cells with reactive oxygen species that damage proteins, lipids, and DNA. Endothelial cells lining blood vessels are particularly vulnerable. Experimental research suggests that even short-duration glucose spikes can impair endothelial function, a precursor to cardiovascular disease, and some studies indicate oscillating glucose may be more harmful in this respect than elevated but stable glucose. Observational research has linked large postprandial glucose spikes to cardiovascular risk, although studies disagree on whether this adds much beyond average glucose and A1C.
The inflammation angle is equally important. Repeated glucose excursions activate inflammatory pathways, including the release of cytokines and the activation of NF-kB signaling. Over time, this chronic low-grade inflammation may contribute to the progression of insulin resistance, a possible self-reinforcing cycle, though how much variability itself drives this in humans is not settled.
There is also growing evidence linking high variability to neurological consequences. Researchers have documented associations between glycemic variability and cognitive performance, including impairments in working memory and processing speed during periods of unstable glucose. These findings are strongest in people with diabetes and are less established in people without it.
CGMs and the Democratization of Metabolic Data
Continuous glucose monitors were initially developed for people with type 1 diabetes, who needed real-time glucose information to safely manage insulin dosing. For years, they remained largely confined to that population. A sensor placed under the skin reads interstitial glucose every few minutes and transmits the data to a smartphone or receiver, building a detailed picture of glucose dynamics over weeks.
The technology has improved dramatically. Earlier generations required frequent fingerstick calibrations and lasted only a few days. Current devices from companies like Dexcom and Abbott (makers of the FreeStyle Libre) are factory-calibrated, last up to 15 days, and integrate directly with smartwatches and health apps. Accuracy has improved to the point where CGMs are now approved for insulin dosing decisions without fingerstick confirmation in many countries.
What changed the cultural conversation was the entry of CGMs into the mainstream wellness market. Starting around 2019 and accelerating through the early 2020s, companies began marketing CGMs to people without diabetes as a tool for optimizing nutrition, energy, and performance. Startups built subscription services around sensor hardware paired with app-based coaching that interpreted glucose data in the context of sleep, exercise, stress, and diet. By 2024, over-the-counter CGMs were available in the United States, and a growing number of non-diabetic users were wearing them for weeks or months.
This democratization has had real scientific value. A Stanford study of 57 adults without diabetes, published in PLOS Biology in 2018, found that even people with normal A1C and fasting glucose could show surprisingly wide glucose variability, and that individuals responded very differently to the same foods. The concept of personalized nutrition, the idea that the same meal can produce very different glucose responses in different people, gained empirical support. Twin studies and microbiome research have begun to explain some of that variability through gut bacterial composition.
For readers who want to explore their own glucose patterns, a continuous glucose monitor for personal use can now be purchased without a prescription in many markets. The data it produces, while requiring careful interpretation, can offer genuinely novel insight into how specific foods, sleep patterns, and stress affect individual metabolism.
What Variability Means for People Without Diabetes
Here is where the science gets both exciting and contentious. Researchers studying non-diabetic populations have found that many people who would never be flagged by standard screening exhibit glucose patterns that resemble early metabolic dysfunction when viewed through a CGM. Large postprandial spikes followed by reactive hypoglycemia (glucose dropping below about 70 mg/dL after a spike) may be more common in the general population than previously recognized, though the evidence is limited.
The same Stanford study found that glucose levels in people classified as normal by standard tests sometimes reached the prediabetic and diabetic ranges when monitored continuously. Whether such swings explain the energy crashes and carbohydrate cravings that many people experience without any clinical diagnosis is a plausible idea, but it remains unproven.
The insulin resistance spectrum is key here. Type 2 diabetes does not appear suddenly. It develops over years, often decades, as insulin sensitivity gradually erodes and the pancreas works harder to compensate. For much of that journey, fasting glucose and A1C remain technically normal because the pancreas is still able to produce enough insulin to force glucose into range. But the cost is high variability, elevated postprandial glucose, and eventually burnout of beta cells. By the time a person is diagnosed with prediabetes, many researchers believe substantial metabolic damage has already occurred.
This makes variability a potentially valuable early warning signal. If high variability reflects the strain of compensating for early insulin resistance, then identifying and addressing it early could interrupt the progression toward diabetes. The challenge is that the scientific community has not yet established clear clinical thresholds for variability in non-diabetic populations. What counts as too much variability for someone without diabetes? That question remains actively debated, and some researchers caution against medicalizing normal physiological fluctuation.
The Limits of the Data: Caution and Context
Not everyone in the scientific community is enthusiastic about the CGM revolution in healthy populations. The concerns are legitimate and worth taking seriously.
First, there is the risk of over-medicalization. Glucose fluctuates constantly as a normal part of metabolism. It rises during exercise even when no food has been consumed, because the liver releases glucose to fuel working muscles. It fluctuates with stress hormones, sleep quality, and the timing of meals. Labeling normal physiological variation as problematic can create anxiety and disordered eating behaviors. Some researchers and dietitians have warned that CGM use in healthy individuals, without proper clinical context, risks pathologizing normal responses.
Second, the wellness industry’s marketing has sometimes outpaced the evidence. Claims that optimizing glucose variability will dramatically improve energy, cognition, and longevity in already-healthy people are extrapolated from data on diabetic populations. The interventional evidence showing that reducing variability in non-diabetic individuals produces measurable health improvements is still limited.
Third, there are socioeconomic equity concerns. CGMs remain expensive. While prices have dropped, a month of continuous monitoring still costs on the order of $100 or more out of pocket in most markets, and insurance coverage for non-diabetic use is essentially nonexistent. This means the metabolic self-knowledge revolution is, for now, largely available to the affluent and health-obsessed, not the populations at highest risk of metabolic disease.
Finally, CGM data requires interpretation. A single spike does not make someone pre-diabetic. Context matters enormously, and without clinical guidance, users can draw wrong conclusions from their data, either dismissing genuinely concerning patterns or panicking over normal variation.
Practical Implications: What the Evidence Actually Supports
Despite the caveats, the body of evidence supporting glycemic variability as a meaningful metabolic marker is substantial and growing. There are practical takeaways that hold up across multiple lines of research.
For people with diagnosed diabetes, the evidence is clearest. Reducing glycemic variability, not just lowering average glucose, is now a recognized therapeutic target. Time in range has been endorsed by major diabetes organizations as a clinical endpoint. Closed-loop insulin delivery systems, which use CGM data to automate insulin dosing, have shown in clinical trials that they reduce both high and low glucose excursions while improving overall control. For anyone managing diabetes, discussing glycemic variability metrics with a clinician is well-supported by current evidence.
For people at high risk of type 2 diabetes, including those with prediabetes, obesity, or strong family history, CGM use as a monitoring and behavior-change tool may have value. Seeing in real time how specific foods and lifestyle choices affect glucose can be a powerful motivator. Seeing one’s own postprandial spikes may help some people stick with dietary changes, although the evidence for lasting benefit is still limited.
For the general healthy population, the picture is murkier but not without value. Understanding that not all carbohydrates affect glucose the same way, that meal composition (the ratio of protein, fat, and fiber to carbohydrate), meal timing, sleep, and exercise all shape glucose dynamics, is genuinely useful nutritional knowledge. You do not necessarily need a CGM to apply it. But for those who are curious about their own metabolic responses, a blood glucose meter kit offers a lower-cost way to spot-check postprandial responses to specific meals, even without continuous monitoring.
Diet quality remains the most evidence-backed lever. High-fiber diets, reduced ultra-processed food consumption, adequate protein, and limiting rapidly digested refined carbohydrates tend to reduce glucose variability, although the size of the effect differs between people. Exercise, particularly moderate aerobic activity after meals, has been shown in multiple studies to blunt postprandial glucose spikes by increasing glucose uptake in muscles. Some small studies suggest even a short walk of around 10 minutes after eating can have a measurable effect.
Sleep is underappreciated. Controlled studies suggest that even a single night of short sleep can reduce insulin sensitivity the following day. Chronically poor sleep is one of the most reliable drivers of metabolic dysfunction, yet it rarely features prominently in glucose-focused interventions. Addressing sleep quality is likely as important as dietary optimization for many people struggling with metabolic issues. For those whose poor sleep is contributing to metabolic disruption, a sleep tracking wearable can help identify patterns and motivate improvement.
Where the Science Is Headed
The field is moving fast. Continuous glucose monitors are likely to become one component of a broader metabolic monitoring ecosystem. Researchers are developing wearable sensors for continuous measurement of lactate, ketones, cortisol, and eventually insulin itself. The combination of multiple biomarkers in real time promises a far more nuanced picture of metabolic health than any single measure can provide.
Researchers are applying artificial intelligence to CGM data in an effort to predict metabolic deterioration, to personalize dietary recommendations based on individual glucose response patterns, and to identify subtypes of metabolic dysfunction that may respond differently to interventions. Early research suggests that glucose variability patterns may help distinguish between different mechanisms of insulin resistance, potentially pointing toward more targeted therapies.
The central lesson of the glycemic variability story is both humbling and empowering. Our standard tools for assessing metabolic health were always approximations, useful but blunt. The rollercoaster hidden inside many people who appear metabolically normal on standard tests represents a genuinely important gap in how medicine has understood and monitored metabolic disease. Filling that gap will require better tools, better evidence, and better clinical frameworks for interpreting continuous data in context. The science is not finished. But the question it is asking, not just what your average blood sugar is, but how wildly and how often it swings, is exactly the right one to be asking.
As an Amazon Associate, The Rough Idea earns from qualifying purchases.